Stock INDOUS6 INDO US BIO-TECH LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Indo Us Bio-Tech Limited

Equities

INDOUS6

INE250Z01010

Biotechnology & Medical Research

Market Closed - Bombay S.E.
Other stock markets
 11:00:56 07/06/2024 BST 		5-day change 1st Jan Change
217.7 INR +3.42% Intraday chart for Indo Us Bio-Tech Limited -4.52% -8.72%
05-02 Indo Us Bio-Tech Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 CI
02-14 Indo Us Bio-Tech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023
Capitalization 1 407.8 311.6 197.5 618.8 2,131
Enterprise Value (EV) 1 468.6 395.4 311.8 746.7 2,245
P/E ratio 23.6 x 12.3 x 4.03 x 8.16 x 28.3 x
Yield - - - 0.37% -
Capitalization / Revenue 1.15 x 0.78 x 0.49 x 1.24 x 3.45 x
EV / Revenue 1.33 x 0.99 x 0.78 x 1.49 x 3.64 x
EV / EBITDA 13.5 x 9.91 x 5.8 x 10.8 x 23.9 x
EV / FCF -6.23 x -12.8 x -7 x -4.74 x -22.3 x
FCF Yield -16.1% -7.79% -14.3% -21.1% -4.48%
Price to Book 3.66 x 1.9 x 0.93 x 1.61 x 3.91 x
Nbr of stocks (in thousands) 11,651 14,563 14,563 18,333 20,052
Reference price 2 35.00 21.40 13.56 33.75 106.2
Announcement Date 05/09/19 07/09/20 06/09/21 09/07/22 08/09/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 296.2 353.5 397.6 401.1 500.6 617.4
EBITDA 1 27.33 34.71 39.91 53.79 69.45 93.97
EBIT 1 25.79 32.31 37.78 51.2 64.99 85.71
Operating Margin 8.71% 9.14% 9.5% 12.76% 12.98% 13.88%
Earnings before Tax (EBT) 1 20.4 28.11 28.64 39.29 53.11 73.87
Net income 1 14.49 20.88 25.35 49 50.63 72.4
Net margin 4.89% 5.91% 6.37% 12.22% 10.11% 11.73%
EPS 2 1.410 1.482 1.741 3.362 4.135 3.754
Free Cash Flow 1 -20 -75.22 -30.79 -44.53 -157.5 -100.5
FCF margin -6.75% -21.28% -7.74% -11.1% -31.46% -16.28%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - 0.1250 -
Announcement Date 20/08/18 05/09/19 07/09/20 06/09/21 09/07/22 08/09/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 64.7 60.9 83.8 114 128 114
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 2.367 x 1.754 x 2.099 x 2.125 x 1.842 x 1.214 x
Free Cash Flow 1 -20 -75.2 -30.8 -44.5 -157 -101
ROE (net income / shareholders' equity) 34.4% 22.2% 16.7% 25.9% 16.9% 15.6%
ROA (Net income/ Total Assets) 10.9% 9.85% 8.06% 8.16% 8.18% 8.57%
Assets 1 133.4 212.1 314.3 600.3 619 845.3
Book Value Per Share 2 4.810 9.550 11.30 14.70 21.00 27.20
Cash Flow per Share 2 0.0700 0.0600 0.1400 0.0900 0.0300 0.0900
Capex 1 4.49 12.9 3.96 19.5 39.7 18.2
Capex / Sales 1.52% 3.66% 1% 4.87% 7.92% 2.95%
Announcement Date 20/08/18 05/09/19 07/09/20 06/09/21 09/07/22 08/09/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
INDO US BIO-TECH LIMITED Stock Indo Us Bio-Tech Limited
-8.72% 52.28M
MODERNA, INC. Stock Moderna, Inc.
+51.85% 57.87B
LONZA GROUP AG Stock Lonza Group AG
+41.42% 40.25B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.25% 39.94B
CELLTRION, INC. Stock Celltrion, Inc.
-5.16% 28.54B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.79% 26.4B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.18% 19.33B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.88% 12.4B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.61% 12.23B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.06% 12.2B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. INDOUS6 Stock
  4. Financials Indo Us Bio-Tech Limited
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW